Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Alcium is a marketed generic small molecule formulation developed by Lloyd Healthcare, an Indian pharmaceutical company specializing in cardiovascular, anti-diabetic, and orthopedic medicines. Listed within Lloyd's orthopedic portfolio, Alcium is indicated for the treatment of musculoskeletal disorders and various orthopedic conditions, including osteoporosis and osteomalacia. The product typically functions as a multi-ingredient supplement containing calcium citrate, cholecalciferol (Vitamin D3), magnesium, and zinc. Its primary mechanism of action involves providing essential substrates for bone mineralization and activating the vitamin D receptor (VDR) to enhance intestinal calcium absorption and maintain mineral homeostasis. As an approved generic product, Alcium is utilized in clinical practice to address calcium deficiencies and support overall bone health.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Alcium.